MagForce Nanotechnologies expands management team

To support 2011 product launch and further developments

MagForce Nanotechnologies, a German specialist in nanotechnology-based cancer treatment, has expanded its management team by creating four new positions.

The Berlin-based company said these new roles will support the launch of its EU-approved therapy for the treatment of brain tumours and the further development of its Nano-Cancer therapy in additional cancer indications.

Christoph Rehfuess joins MagForce as director of intellectual property. He is a European patent attorney with 12years of experience in the biotech intellectual property field at Medigene. He takes responsibility for patents, trademarks, and technical contracts.

Dirk Kautz takes the role of director of business/corporate development. Prior to joining MagForce, he worked for more than 13 years in the medical devices industry, holding management positions in marketing and corporate development at, among others, Nihon Kohden and Biotronik.

Kajo Wiest joins as director of finance and controlling and brings with him more than 10 years of finance and controlling experience at Jerini.

Stacy Wiedenmann becomes director of investor relations and corporate communications and brings with her over 10 years of experience. She has also worked at Jerini.

The fifth new recruit is Hans Joachim Hutt, who will support the company in the area of medical affairs. The firm said his medical training and more than 20 years of experience at pharmaceutical companies, including Boehringer Ingelheim, Sanofi, Bristol-Myers Squibb, and Sanofi Pasteur MSD, will help MagForce establish commercial networks and expand its therapeutic applications.

‘Filling these key company positions is an important step in the transformation of the company from a research and development only business into a commercial company. Additional hiring for the sales and marketing team will be completed by the end of the year,’ said Peter Heinrich, ceo of MagForce.

You may also like

Research & Development

Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research

Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development

PSI launches platform to speed up site ID, startup and enrolment in pivotal studies

SYNETIC is designed to speed up site identification, startup and patient enrollment in pivotal clinical trials
Ingredients

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery
Pharmaceutical

PharmNovo enhances its board ahead of Phase II development

The new board members bring complementary experience in drug development, clinical execution and partnering, supporting the company’s continued progress and dialogue with potential partners
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Research & Development

Baseline Therapuetics launches to advance GLP-1 Phase III Programme in Alcohol Use Disorder

The clinical-stage biotech has launched to progress BT-001, a once-weekly GLP-1 receptor agonist, into FDA-aligned Phase III trials for alcohol use disorder, with studies planned to begin in 2026
Research & Development

Researchers identify early signs of Parkinson's in the blood

Researchers at Chalmers University of Technology have identified early-stage Parkinson’s disease biomarkers detectable in blood, revealing a limited diagnostic window that could enable screening and earlier intervention years before motor symptoms appear
Subscribe now